NKp30-CD137 CAR T cells

NKp30-CD137 CAR T cells are a type of engineered cellular immunotherapy in which human T cells are redirected to recognize and attack tumor cells via expression of a chimeric antigen receptor (CAR) composed of the extracellular domain of human NKp30 fused to a CD137 (4-1BB) intracellular co-stimulatory signaling domain and the CD3ζ activation domain. The CAR is introduced into T cells using retroviral vectors, and cells can be further modified by CRISPR/Cas9-mediated knockout of the endogenous T cell receptor (TCR) to prevent graft-versus-host disease in allogeneic settings. These CAR T cells target the B7H6 surface antigen, which is expressed on various human tumor cell lines including acute myeloid leukemia (AML) and melanoma. NKp30-CD137 CAR T cells mediate cytotoxicity and cytokine release (e.g., IFN-γ) upon target cell engagement. Preclinical studies have shown potent anti-tumor activity in vitro and transient anti-tumor efficacy in vivo in xenograft mouse models of melanoma. Their activity profile in AML and other B7H6-positive cancers is under preclinical investigation[1][2].

Other names

NKp30 CAR TCR KO T cellsNKp-30 CAR TCR KO T cellsNKp 30 CAR TCR KO T cellsNKp30-4-1BB CAR T cellsNKp-30-4-1BB CAR T cellsNKp 30-4-1BB CAR T cells